Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies.

ABSTRACT: Treosulfan-based conditioning prior to allogeneic transplantation has been shown to have myeloablative, immunosuppressive, and antineoplastic effects associated with reduced non-relapse mortality (NRM) in adults. Therefore, we prospectively evaluated the safety and efficacy of treosulfan-based conditioning in children with hematological malignancies in this phase II trial. Overall, 65 children with acute lymphoblastic leukemia (35.4%), acute myeloid leukemia (44.6%), myelodysplastic syndrome (15.4%), or juvenile myelomonocytic leukemia (4.6%) received treosulfan intravenously at a dose of 10 mg/m²/day (7.7%), 12 g/m²/day (35.4%), or 14 g/m²/day (56.9%) according to their individual body surface area in combination with fludarabine and thiotepa. The incidenc

SUBMITTER: Kalwak K 

PROVIDER: S-EPMC7515850 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature